Specializing in large-scale, multi-omics biomarker discovery.

Biomarker discovery services for insights beyond measure.

While the vast majority of biomarker discovery to date has focused on genomics, >80% of disease risk stems from non-genetic factors and exposures over time. This molecular landscape has remained largely unexplored, until now.

Sapient’s innovative technologies finally enable rapid, large-scale profiling of metabolite, lipid, and protein biomarkers, which read out dynamic factors influencing health and disease – measuring thousands of biomarkers per sample, across thousands of samples at a time.

Supported by an advanced biocomputational framework for analysis of multi-omics datasets, we deliver data insights to elucidate disease mechanisms, subtype diseases, and ultimately improve the precision and efficacy of therapies.

Discovery Metabolomics & Lipidomics

Target Metabolite & Lipid Panels

Discovery Proteomics

Targeted Proteomics

Biocomputational Analysis

What questions can you answer via our biomarker discovery services?

We build our data generation and analysis approaches around your context of use, helping you define experiments that give you the data you need for the phase you’re in. This could include identification and analysis of biomarkers that inform:

Target Identification

Identify differentially expressed, disease-modifying, and tractable therapeutic targets that can be acted upon by your drug.

Target Validation

Confirm a target’s role in disease process and/or the effects of pharmacological modulation of the target.

Target Engagement

Demonstrate the drug reaches its intended target with measurable binding effect.

Pharmacodynamics

Evaluate the biological activity of a drug.

Early Disease Detection

Identify genetic and/or environmental factors that predispose to disease and/or cause disease progression.

Disease Progression

Monitor disease status, the occurrence of new disease effects, and/or change in disease severity.

Patient Stratification

Select patients according to disease-based or drug-based biomarker signatures.

Clinical Trial Enrichment

Select patients most likely to respond to a treatment to increase study power while reducing study size.

Safety Profiling

Assess the presence or extent of toxicity related to an intervention or drug exposure.

Companion Diagnostics

Identify predictive biomarkers that identify suitable patients for a treatment.

Ready to discover more?

Connect with our scientists to discuss your project or the biological questions you want to answer. We’re here to help apply our unique biomarker discovery services at any phase of development.

Book a Meeting